MedDataX Logo

COVID-19 Booster Readiness Survey

NCT ID: NCT05529030

Last Updated: 2022-09-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12036 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-01

Study Completion Date

2022-09-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this administrative survey is to inform health system logistics by assessing the attitudes towards towards the bivalent COVID-19 boosters held by healthcare workers (HCWs) at a large, rural health system. It will also test, prospectively, the effect on interest in the bivalent COVID-19 booster of different framing approaches in a survey question sent to employees of a large, rural health system.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Food and Drug Administration has authorized two bivalent COVID-19 boosters with the expectation that the Centers for Disease Control will soon recommend them. The researchers plan to survey the HCWs at a large, rural health system on their attitudes on the bivalent booster.

This survey will gather data on HCWs' interest in a bivalent booster, reasons for hesitancy, risk perception about COVID-19 infection and its complications, and prior COVID-19 infection and vaccination.

Respondents will also be randomly assigned to see different versions of the question asking if they are interested in a bivalent booster with different framing approaches, such as protection of the self or protection of patients (for patient-facing employees). Information on prior vaccination and perceptions of risk will also be gathered and used as covariates in the analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaccination Refusal

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Communication Surveys and Questionnaires Vaccination Economics, Behavioral

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants
Participants will not know that there are different versions of surveys

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard question

Question with no additional text or framing

Group Type NO_INTERVENTION

No interventions assigned to this group

Question with salient Omicron message

Question indicates that the bivalent booster can protect the respondent from the Omicron variant

Group Type EXPERIMENTAL

Salience of Omicron variant

Intervention Type BEHAVIORAL

The message mentions the Omicron variant, which can be a fear appeal or make salient the reason for the new booster

Self-protection message

Intervention Type BEHAVIORAL

The message makes a reference to protecting one's self

Question with patient protection message

Question indicates that the bivalent booster can protect patients (only presented to patient-facing employees)

Group Type EXPERIMENTAL

Other-protection message

Intervention Type BEHAVIORAL

The message makes a reference to protecting others (patients)

Question with salient Omicron and patient protection message

Question indicates that the bivalent booster can protect patients from the Omicron variant (only presented to patient-facing employees)

Group Type EXPERIMENTAL

Salience of Omicron variant

Intervention Type BEHAVIORAL

The message mentions the Omicron variant, which can be a fear appeal or make salient the reason for the new booster

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Salience of Omicron variant

The message mentions the Omicron variant, which can be a fear appeal or make salient the reason for the new booster

Intervention Type BEHAVIORAL

Self-protection message

The message makes a reference to protecting one's self

Intervention Type BEHAVIORAL

Other-protection message

The message makes a reference to protecting others (patients)

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Employee at the health system
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Geisinger Clinic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michelle N. Meyer

Faculty Co-Director, Behavioral Insights Team, Geisinger Clinic

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michelle N Meyer, PhD

Role: PRINCIPAL_INVESTIGATOR

Geisinger Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Geisinger Clinic

Danville, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-0726

Identifier Type: -

Identifier Source: org_study_id